Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two blood tests may separate real kidney harm from a false alarm

NCT ID NCT07818265

Knowledge-focused Sponsor: King Faisal Specialist Hospital & Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Doctors often see creatinine rise in patients taking vancomycin plus piperacillin-tazobactam, a common antibiotic pair. It is unclear whether that rise means real kidney injury or a harmless lab change. This study follows 304 adults on either that pair or vancomycin plus meropenem, measuring both creatinine and cystatin C to compare true kidney injury rates between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the two-marker approach works, doctors could tell true kidney damage from a harmless lab change and choose antibiotics with more confidence.
What could go wrong
This observational study cannot prove cause and effect, and its findings may not apply to patients with advanced kidney disease or those on dialysis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 304 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to King Faisal Specialist Hospital and Research Center, and received vancomycin combined with either piperacillin-tazobactam or meropenem from August 2026 until achieving the pre-specified sample size will be screened for the inclusion and exclusion criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Receipt of vancomycin in combination with either piperacillin-tazobactam or meropenem, with both antimicrobial agents prescribed by the treating physician and expected to be administered concomitantly for \>48 hours. Exclusion Criteria: * Known advanced chronic kidney disease (CKD), defined as a baseline estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m², or dialysis dependence.. * Pregnancy. * Receipt of renal replacement therapy prior to enrollment. * Obstructive uropathy causing AKI. * Recipients of solid organ transplant or hematopoietic stem cell transplantation within one year of presentation * Concomitant receive of agents known to be nephrotoxins: Amphotericin B Aminoglycosides Calcineurin inhibitors * Patients with AKI 30 days prior to vancomycin initiation * Admission to the ICU for indication other than postoperative care for \> 72 hours * Receiving vancomycin therapy within 30 days before the index combination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury bacterial infectious disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Bacterial infections Nephrotoxicity Renal impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Faisal Specialist Hospital and Research Center-Riyadh

    Riyadh, 11211, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.